Anticancer DNA vaccine based on human telomerase reverse transcriptase generates a strong and specific T cell immune response

OncoImmunology

Volumn 5, Issue 3, 2016, Pages

  Thalmensi, Jessie ^a   Pliquet, Elodie ^a,b   Liard, Christelle ^a   Escande, Marie ^a   Bestetti, Thomas ^a   Julithe, Marion ^a   Kostrzak, Anna ^a   Pailhes Jimenez, Anne Sophie ^a   Bourges, Emanuèle ^a   Loustau, Maria ^a   Caumartin, Julien ^a   Lachgar, Abderrahim ^a   Huet, Thierry ^a   Wain Hobson, Simon ^a,b   Langlade Demoyen, Pierre ^a,b  

^a Invectys   (France)

^b INSTITUT PASTEUR   (France)

Author keywords

Cancer; DNA vaccines; electrogene transfer; electroporation; hTERT; immunotherapy

Indexed keywords

CANCER VACCINE; GAMMA INTERFERON; INTERLEUKIN 2; INVAC 1; TELOMERASE REVERSE TRANSCRIPTASE; TUMOR ANTIGEN; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER IMMUNOTHERAPY; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY ASSAY; ENZYME LINKED IMMUNOSPOT ASSAY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; MOUSE; NONHUMAN; PROTEIN EXPRESSION; SARCOMA; T LYMPHOCYTE; TUMOR GROWTH; VACCINATION;

EID: 84961575378     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.1080/2162402X.2015.1083670     Document Type: Article

References (52)

1. L.Novellino, C.Castelli, G.Parmiani. A listing of human tumor antigens recognized by T cells: march 2004 update. Cancer Immunol Immunother 2005; 54:187-207; PMID:15309328; http://dx.doi.org/10.1007/s00262-004-0560-6
2. K.Collins, J.R.Mitchell. Telomerase in the human organism. Oncogene 2002; 21:564-79; PMID:11850781; http://dx.doi.org/10.1038/sj.onc.1205083
3. D.Hanahan, R.A.Weinberg. Hallmarks of cancer: the next generation. Cell 2011; 144:646-74; PMID:21376230; http://dx.doi.org/10.1016/j.cell.2011.02.013
4. J.W.Shay, S.Bacchetti. A survey of telomerase activity in human cancer. Euro J Cancer 1997; 33:787-91; PMID:9282118; http://dx.doi.org/10.1016/S0959-8049(97)00062-2
5. C.Q.Zhu, J.C.Cutz, N.Liu, D.Lau, F.A.Shepherd, J.A.Squire, M.S.Tsao. Amplification of telomerase (hTERT) gene is a poor prognostic marker in non-small-cell lung cancer. Brit J Cancer 2006; 94:1452-9; PMID:16641908; http://dx.doi.org/10.1038/sj.bjc.6603110
6. M.Zanetti, X.Hernandez, P.Langlade-Demoyen. Telomerase reverse transcriptase as target for anti-tumor T cell responses in humans. Springer Semin Immunopathol 2005; 27:87-104; PMID:15711953; http://dx.doi.org/10.1007/s00281-004-0197-8
7. G.L.Beatty, R.H.Vonderheide. Telomerase as a universal tumor antigen for cancer vaccines. Expert Rev Vaccines 2008; 7:881-7; PMID:18767939; http://dx.doi.org/10.1586/14760584.7.7.881
8. C.B.Harley. Telomerase and cancer therapeutics. Nat Rev Cancer 2008; 8:167-79; PMID:18256617; http://dx.doi.org/10.1038/nrc2275
9. J.A.Berzofsky, M.Terabe, S.Oh, I.M.Belyakov, J.D.Ahlers, J.E.Janik, J.C.Morris. Progress on new vaccine strategies for the immunotherapy and prevention of cancer. J Clin Investigat 2004; 113:1515-25; PMID:15173875; http://dx.doi.org/10.1172/JCI21926
10. J.Rice, C.H.Ottensmeier, F.K.Stevenson. DNA vaccines: precision tools for activating effective immunity against cancer. Nat Rev Cancer 2008; 8:108-20; PMID:18219306; http://dx.doi.org/10.1038/nrc2326
11. D.Fioretti, S.Iurescia, V.M.Fazio, M.Rinaldi. DNA vaccines: developing new strategies against cancer. J Biomed Biotechnol 2010; 2010:174378; PMID:20368780; http://dx.doi.org/10.1155/2010/174378
12. M.A.Liu. DNA vaccines: a review. J Int Med 2003; 253:402-10; PMID:12653868; http://dx.doi.org/10.1046/j.1365-2796.2003.01140.x
13. C.Y.Calvet, J.Thalmensi, C.Liard, E.Pliquet, T.Bestetti, T.Huet, P.Langlade-Demoyen, L.M.Mir. Optimization of a gene electrotransfer procedure for efficient intradermal immunization with an hTERT-based DNA vaccine in mice. Mol Ther — Methods Clin Dev 2014; 1:14045; PMID:26015983; http://dx.doi.org/10.1038/mtm.2014.45
14. M.A.Kutzler, D.B.Weiner. DNA vaccines: ready for prime time? Nat Rev Genet 2008; 9:776-88; PMID:18781156; http://dx.doi.org/10.1038/nrg2432
15. W.C.Drosopoulos, V.R.Prasad. The active site residue Valine 867 in human telomerase reverse transcriptase influences nucleotide incorporation and fidelity. Nucleic Acids Res 2007; 35:1155-68; PMID:17264120; http://dx.doi.org/10.1093/nar/gkm002
16. Q.Wang, C.Lei, H.Wan, Q.Liu. Improved cellular immune response elicited by a ubiquitin-fused DNA vaccine against Mycobacterium tuberculosis. DNA Cell Biol 2012; 31:489-95; PMID:21905875; http://dx.doi.org/10.1089/dna.2011.1309
17. P.P.Lee, C.Yee, P.A.Savage, L.Fong, D.Brockstedt, J.S.Weber, D.Johnson, S.Swetter, J.Thompson, P.D.Greenberg Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients. Nat Med 1999; 5:677-85; PMID:10371507; http://dx.doi.org/10.1038/9525
18. P.R.Dunbar, C.L.Smith, D.Chao, M.Salio, D.Shepherd, F.Mirza, M.Lipp, A.Lanzavecchia, F.Sallusto, A.Evans A shift in the phenotype of melan-A-specific CTL identifies melanoma patients with an active tumor-specific immune response. J Immunol 2000; 165:6644-52; PMID:11086110; http://dx.doi.org/10.4049/jimmunol.165.11.6644
19. K.Palucka, H.Ueno, J.Banchereau. Recent developments in cancer vaccines. J Immunol 2011; 186:1325-31; PMID:21248270; http://dx.doi.org/10.4049/jimmunol.0902539
20. Y.Godet, E.Fabre, M.Dosset, M.Lamuraglia, E.Levionnois, P.Ravel, N.Benhamouda, A.Cazes, F.Le Pimpec-Barthes, B.Gaugler Analysis of spontaneous tumor-specific CD4 T-cell immunity in lung cancer using promiscuous HLA-DR telomerase-derived epitopes: potential synergistic effect with chemotherapy response. Clin Cancer Res 2012; 18:2943-53; PMID:22407833; http://dx.doi.org/10.1158/1078-0432.CCR-11-3185
21. H.A.Andersson, M.A.Barry. Maximizing antigen targeting to the proteasome for gene-based vaccines. Mol Ther 2004; 10:432-46; PMID:15336644; http://dx.doi.org/10.1016/j.ymthe.2004.05.035
22. A.Endmann, M.Baden, E.Weisermann, K.Kapp, M.Schroff, C.Kleuss, B.Wittig, C.Juhls. Immune response induced by a linear DNA vector: influence of dose, formulation and route of injection. Vaccine 2010; 28:3642-9; PMID:20362204; http://dx.doi.org/10.1016/j.vaccine.2010.03.034
23. J.F.Nicolas, B.Guy. Intradermal, epidermal and transcutaneous vaccination: from immunology to clinical practice. Expert Rev Vaccines 2008; 7:1201-14; PMID:18844594; http://dx.doi.org/10.1586/14760584.7.8.1201
24. M.L.Bagarazzi, J.Yan, M.P.Morrow, X.Shen, R.L.Parker, J.C.Lee, M.Giffear, P.Pankhong, A.S.Khan, K.E.Broderick Immunotherapy against HPV16/18 generates potent TH1 and cytotoxic cellular immune responses. Sci Translat Med 2012; 4:155ra38; PMID:23052295; http://dx.doi.org/10.1126/scitranslmed.3004414
25. A.Gothelf, J.Gehl. What you always needed to know about electroporation based DNA vaccines. Hum Vaccines Immunother 2012; 8:1694-702; PMID:23111168; http://dx.doi.org/10.4161/hv.22062
26. M.Elnekave, K.Furmanov, A.H.Hovav. Intradermal naked plasmid DNA immunization: mechanisms of action. Expert Rev Vaccines 2011; 10:1169-82; PMID:21854310; http://dx.doi.org/10.1586/erv.11.66
27. P.A.Antony, C.A.Piccirillo, A.Akpinarli, S.E.Finkelstein, P.J.Speiss, D.R.Surman, D.C.Palmer, C.C.Chan, C.A.Klebanoff, W.W.Overwijk CD8+ T cell immunity against a tumor/self-antigen is augmented by CD4+ T helper cells and hindered by naturally occurring T regulatory cells. J Immunol 2005; 174:2591-601; PMID:15728465; http://dx.doi.org/10.4049/jimmunol.174.5.2591
28. M.R.Parkhurst, J.P.Riley, T.Igarashi, Y.Li, P.F.Robbins, S.A.Rosenberg. Immunization of patients with the hTERT:540-548 peptide induces peptide-reactive T lymphocytes that do not recognize tumors endogenously expressing telomerase. Clin Cancer Res 2004; 10:4688-98; PMID:15269141; http://dx.doi.org/10.1158/1078-0432.CCR-04-0325
29. R.Kim, M.Emi, K.Tanabe. Cancer immunoediting from immune surveillance to immune escape. Immunology 2007; 121:1-14; PMID:17386080; http://dx.doi.org/10.1111/j.1365-2567.2007.02587.x
30. R.A.Seder, P.A.Darrah, M.Roederer. T-cell quality in memory and protection: implications for vaccine design. Nat Rev Immunol 2008; 8:247-58; PMID:18323851; http://dx.doi.org/10.1038/nri2274
31. D.T.Fisher, Q.Chen, M.M.Appenheimer, J.Skitzki, W.C.Wang, K.Odunsi, S.S.Evans. Hurdles to lymphocyte trafficking in the tumor microenvironment: implications for effective immunotherapy. Immunol Investigat 2006; 35:251-77; PMID:16916754; http://dx.doi.org/10.1080/08820130600745430
32. J.Galon, A.Costes, F.Sanchez-Cabo, A.Kirilovsky, B.Mlecnik, C.Lagorce-Pages, M.Tosolini, M.Camus, A.Berger, P.Wind Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006; 313:1960-4; PMID:17008531; http://dx.doi.org/10.1126/science.1129139
33. E.Sato, S.H.Olson, J.Ahn, B.Bundy, H.Nishikawa, F.Qian, A.A.Jungbluth, D.Frosina, S.Gnjatic, C.Ambrosone, Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci U S A 2005; 102:18538-43; PMID:16344461; http://dx.doi.org/10.1073/pnas.0509182102
34. V.Appay, C.Jandus, V.Voelter, S.Reynard, S.E.Coupland, D.Rimoldi, D.Lienard, P.Guillaume, A.M.Krieg, J.C.Cerottini New generation vaccine induces effective melanoma-specific CD8+ T cells in the circulation but not in the tumor site. J Immunol 2006; 177:1670-8; PMID:16849476; http://dx.doi.org/10.4049/jimmunol.177.3.1670
35. R.A.Greenberg, R.C.Allsopp, L.Chin, G.B.Morin, R.A.DePinho. Expression of mouse telomerase reverse transcriptase during development, differentiation and proliferation. Oncogene 1998; 16:1723-30; PMID:9582020; http://dx.doi.org/10.1038/sj.onc.1201933
36. J.Hernandez, F.Garcia-Pons, Y.C.Lone, H.Firat, J.D.Schmidt, P.Langlade-Demoyen, M.Zanetti. Identification of a human telomerase reverse transcriptase peptide of low affinity for HLA A2.1 that induces cytotoxic T lymphocytes and mediates lysis of tumor cells. Proc Natl Acad Sc U S A 2002; 99:12275-80; PMID:12218171; http://dx.doi.org/10.1073/pnas.182418399
37. B.Minev, J.Hipp, H.Firat, J.D.Schmidt, P.Langlade-Demoyen, M.Zanetti. Cytotoxic T cell immunity against telomerase reverse transcriptase in humans. Proc Natl Acad Sci U S A 2000; 97:4796-801; PMID:10759561; http://dx.doi.org/10.1073/pnas.070560797
38. T.Yamano, Y.Kaneda, S.H.Hiramatsu, S.Huang, A.N.Tran, A.E.Giuliano, D.S.Hoon. Immunity against breast cancer by TERT DNA vaccine primed with chemokine CCL21. Cancer Gene Ther 2007; 14:451-9; PMID:17318199; http://dx.doi.org/10.1038/sj.cgt.7701035
39. J.Yan, P.Pankhong, T.H.Shin, N.Obeng-Adjei, M.P.Morrow, J.N.Walters, A.S.Khan, N.Y.Sardesai, D.B.Weiner. Highly optimized DNA vaccine targeting human telomerase reverse transcriptase stimulates potent antitumor immunity. Cancer Immunol Res 2013; 1:179-89; PMID:24777680; http://dx.doi.org/10.1158/2326-6066.CIR-13-0001
40. T.De Pas, M.Giovannini, M.Rescigno, C.Catania, F.Toffalorio, G.Spitaleri, A.Delmonte, M.Barberis, L.Spaggiari, P.Solli Vaccines in non-small cell lung cancer: rationale, combination strategies and update on clinical trials. Crit Rev Oncol/Hematol 2012; 83:432-43; PMID:22366114; http://dx.doi.org/10.1016/j.critrevonc.2011.12.005
41. M.Mkrtichyan, Y.G.Najjar, E.C.Raulfs, M.Y.Abdalla, R.Samara, R.Rotem-Yehudar, L.Cook, S.N.Khleif. Anti-PD-1 synergizes with cyclophosphamide to induce potent anti-tumor vaccine effects through novel mechanisms. Euro J Immunol 2011; 41:2977-86; PMID:21710477; http://dx.doi.org/10.1002/eji.201141639
42. W.J.Lesterhuis, I.J.de Vries, E.A.Aarntzen, A.de Boer, N.M.Scharenborg, M.van de Rakt, D.J.van Spronsen, F.W.Preijers, C.G.Figdor, G.J.Adema A pilot study on the immunogenicity of dendritic cell vaccination during adjuvant oxaliplatin/capecitabine chemotherapy in colon cancer patients. Brit J Cancer 2010; 103:1415-21; PMID:20924373; http://dx.doi.org/10.1038/sj.bjc.6605935
43. Y.Yang, Y.Chen, C.Zhang, H.Huang, S.M.Weissman. Nucleolar localization of hTERT protein is associated with telomerase function. Exp Cell Res 2002; 277:201-9; PMID:12083802; http://dx.doi.org/10.1006/excr.2002.5541
44. A.Bachmair, D.Finley, A.Varshavsky. In vivo half-life of a protein is a function of its amino-terminal residue. Science 1986; 234:179-86; PMID:3018930; http://dx.doi.org/10.1126/science.3018930
45. A.E.Carnes, J.M.Luke, J.M.Vincent, S.Anderson, A.Schukar, C.P.Hodgson, J.A.Williams. Critical design criteria for minimal antibiotic-free plasmid vectors necessary to combine robust RNA Pol II and Pol III-mediated eukaryotic expression with high bacterial production yields. J Gene Med 2010; 12:818-31; PMID:20806425; http://dx.doi.org/10.1002/jgm.1499
46. J.Luke, A.E.Carnes, C.P.Hodgson, J.A.Williams. Improved antibiotic-free DNA vaccine vectors utilizing a novel RNA based plasmid selection system. Vaccine 2009; 27:6454-9; PMID:19559109; http://dx.doi.org/10.1016/j.vaccine.2009.06.017
47. A.Pajot, M.L.Michel, N.Fazilleau, V.Pancre, C.Auriault, D.M.Ojcius, F.A.Lemonnier, Y.C.Lone. A mouse model of human adaptive immune functions: HLA-A2.1-/HLA-DR1-transgenic H-2 class I-/class II-knockout mice. Eur J Immunol 2004; 34:3060-9; PMID:15468058; http://dx.doi.org/10.1002/eji.200425463
48. P.S.Rohrlich, S.Cardinaud, H.Firat, M.Lamari, P.Briand, N.Escriou, F.A.Lemonnier. HLA-B*0702 transgenic, H-2KbDb double-knockout mice: phenotypical and functional characterization in response to influenza virus. Int Immunol 2003; 15:765-72; PMID:12750360; http://dx.doi.org/10.1093/intimm/dxg073
49. O.Adotevi, K.Mollier, C.Neuveut, S.Cardinaud, E.Boulanger, B.Mignen, W.H.Fridman, M.Zanetti, P.Charneau, E.Tartour Immunogenic HLA-B*0702-restricted epitopes derived from human telomerase reverse transcriptase that elicit antitumor cytotoxic T-cell responses. Clin Cancer Res 2006; 12:3158-67; PMID:16707616; http://dx.doi.org/10.1158/1078-0432.CCR-05-2647
50. X.Cortez-Gonzalez, J.Sidney, O.Adotevi, A.Sette, F.Millard, F.Lemonnier, P.Langlade-Demoyen, M.Zanetti. Immunogenic HLA-B7-restricted peptides of hTRT. Int Immunol 2006; 18:1707-18; PMID:17077179; http://dx.doi.org/10.1093/intimm/dxl105
51. M.Durward, J.Harms, G.Splitter. Antigen specific killing assay using CFSE labeled target cells. J Visualized Exp 2010; PMID:21085108; http://dx.doi.org/10.3791/2250
52. P.Workman, E.O.Aboagye, F.Balkwill, A.Balmain, G.Bruder, D.J.Chaplin, J.A.Double, J.Everitt, D.A.Farningham, M.J.Glennie Guidelines for the welfare and use of animals in cancer research. Brit J Cancer 2010; 102:1555-77; PMID:20502460; http://dx.doi.org/10.1038/sj.bjc.6605642